Glenmark launches RYALTRIS® in Brazil

Launch introduces Glenmark's differentiated dual-action therapy for allergic rhinitis in Brazil

Further strengthens Glenmark's innovation-led respiratory portfolio and expands access across Latin America

SAO PAULO and MUMBAI, India, Sept. 11, 2026 /PRNewswire/ -- Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), today announced the launch of RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older. The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (ANVISA) earlier this year¹.

The launch reflects Glenmark's continued commitment to advancing its respiratory innovation journey and reinforces the Company's continued progress in expanding access to differentiated therapies across global markets.

Allergic rhinitis is a highly prevalent chronic condition in Brazil, affecting an estimated 20–30% of the population, equivalent to nearly 40–60 million people^2,3. This significant disease burden highlights the need for effective, convenient, and differentiated treatment options for patients across the country.

The launch of RYALTRIS® introduces the first olopatadine-containing intranasal combination therapy in Brazil, combining an antihistamine (olopatadine hydrochloride) and a corticosteroid (mometasone furoate) in a single nasal spray. This offers a differentiated dual-action treatment option for symptoms associated with allergic rhinitis.

Commenting on the launch, Marco Cerato, Executive Vice President & Global Head – Innovative Business, Glenmark Pharmaceuticals, said, "The launch of RYALTRIS® in Brazil marks a significant milestone for our innovative respiratory portfolio and reflects our continued commitment to advancing respiratory care through science-led innovation and a patient-centric approach. As the largest healthcare market in Latin America, Brazil provides a strategic opportunity to bring this differentiated treatment option to patients and healthcare professionals."

RYALTRIS® is Glenmark's first globally commercialized branded innovative product and has already been approved in 57 markets worldwide, including the United States, European Union, United Kingdom, Australia, South Korea, Russia, and China.

References:

1. Ryaltris® label (Ryaltris® bula profissional - excipiente 14/05/2026). Accessed: Jun. 15, 2026. [Online]. Available: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=ryaltris 
2. Solé D, et al. V Brazilian Consensus on Rhinitis – 2024. Braz J Otorhinolaryngol. 2025;91(1):101500.
3. Urrutia-Pereira M, et al. Prevalence of rhinitis and associated factors in adolescents and adults: a Global Asthma Network study. Rev Paul Pediatr. 2023;41:e2021400.

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a global, research‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com.